Hopeful news.

DPP-4 inhibitors may contribute to a lowered risk and progression of acute respiratory complications for people with type 2 diabetes and COVID-19.

According to commentary in Diabetes Research and Clinical Practice, Endocrinologist Gianluca Iacobellis, MD, Ph.D. suggests that DPP-4 inhibitors could help decrease COVID-19-related immune overreaction in people with diabetes. This immune system calming is due to DPP-IVs anti-inflammatory effects.

All told, DPP-4 “may represent a potential target for preventing and reducing the risk and the progression of the acute respiratory complications that Type 2 diabetes may add to the COVID-19 infection,” Iacobellis wrote in his article.

Based on data from the Chinese city of Wuhan and Italy, people with type 2 diabetes are at higher risk of serious disease in the current pandemic. The data indicates that people with diabetes have accounted for a large proportion of intensive care admission and deaths related to COVID-19.

“The body is overreacting with this inflammatory response to the virus,” Dr. Iacobellis said in a statement. “This could be partially mediated by DPP-4. The virus binds to the enzyme and the enzymatic activity of DPP4 overexpresses inflammatory cytokines, exaggerating the inflammatory response.”

Read more FierceBiotech

---

Diabetes 2020 – Virtual Conference!
Now with COVID-19 Update
7.5 CEs | $89 | Starts April 23

The COVID Pandemic is taking a toll on people with diabetes. What is the critical information Diabetes Care and Education Specialists need as we navigate this pandemic? How can take a leadership role in providing sound recommendations while helping to manage the full range of diabetes issues, including hypertension, hyperlipidemia, and cardiovascular risk reduction?

Coach Beverly has created this four-session virtual course so that participants can delve deep into the topics that are most pressing for diabetes care now and in the future. We will focus on improving population health and then drill down to individual intervention through case studies. We will discuss implementing cardiovascular risk screening and treatment in the clinical setting and more!

Course Schedule

Session 1 – Getting to the Heart of Care – 1.5 CEs – Airs April 23rd

• Our role as Diabetes Care and Education Specialists
• Diabetes and the COVID Pandemic
• ADA and 2020 Medication Management Algorithm –

Session 2 – Cardiovascular Risk Reduction Strategies – 1.5 CEs – Airs April 24th

• ADA and AACE Guidelines for CV Risk Reduction
• Implement Risk Reduction Strategies
• Addressing Hypertension, Lipids and Weight – A Case Study Approach

Session 3 – Lower Extremity Assessment and Intervention – 1.5 CEs – Airs April 28th

• Peripheral Arterial Disease vs Vascular Disease
• Lower extremity assessment techniques
• Prevention strategies and education

Session 4 – Making meaningful Connections and a Vision for the Future – 1.5 CEs – Airs April 30th

• Adverse Child Experiences – ACE and Impact of Diabetes and other Health Outcomes
• Improving health- From individuals to populations

---

Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. Tuesday is our Question of the Week. It’s Informative and FREE!  Sign up below!

[yikes-mailchimp form=”1″]